Cargando…

The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma

OBJECTIVE: Although the prognostic role of BRAF(V600E) mutation in papillary thyroid carcinoma (PTC) is controversial, the American Thyroid Association (ATA) includes the mutational status in their risk stratification system. To evaluate the impact of the BRAF(V600E) mutation status on PTC risk stra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheffel, Rafael Selbach, de Cristo, Ana Patrícia, Romitti, Mirian, Vargas, Carla Vaz Ferreira, Ceolin, Lucieli, Zanella, André B., Dora, Jose Miguel, Maia, Ana Luiza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Endocrinologia e Metabologia 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528629/ https://www.ncbi.nlm.nih.gov/pubmed/34033285 http://dx.doi.org/10.20945/2359-3997000000285

Ejemplares similares

The long and still uncertain journey of BRAF as a prognostic tool in patients with papillary thyroid cancer
por: Scheffel, Rafael Selbach, et al.
Publicado: (2019)

Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET Polymorphisms
por: Ceolin, Lucieli, et al.
Publicado: (2011)

Advanced medullary thyroid cancer: pathophysiology and management
por: Ferreira, Carla Vaz, et al.
Publicado: (2013)

Role of VEGF-A and Its Receptors in Sporadic and MEN2-Associated Pheochromocytoma
por: Ferreira, Carla Vaz, et al.
Publicado: (2014)

Impact of the updated TNM staging criteria on prediction of persistent disease in a differentiated thyroid carcinoma cohort
por: Nava, Carla Fernanda, et al.
Publicado: (2019)

Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma
por: Nava, Carla Fernanda, et al.
Publicado: (2019)

Effect of 3′UTR RET Variants on RET mRNA Secondary Structure and Disease Presentation in Medullary Thyroid Carcinoma
por: Ceolin, Lucieli, et al.
Publicado: (2016)

Effect of Suppressive Levothyroxine Therapy on Bone Mineral Density in Young Patients with Differentiated Thyroid Carcinoma
por: Zanella, André Borsatto, et al.
Publicado: (2022)

Effect of COVID-19 pandemic on diagnosis and treatment of thyroid cancer in Brazil
por: Silveira, Vitor Bock, et al.
Publicado: (2022)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

BRAF V600E and lymph node metastases in papillary thyroid cancer
por: Chen, Pan, et al.
Publicado: (2020)

Prognostic implications of the BRAF-V600(E) mutation in papillary thyroid carcinoma based on a new cut-off age stratification
por: Gan, Xiaoxiong, et al.
Publicado: (2020)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
por: Yan, Changjiao, et al.
Publicado: (2019)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

Sacral metastases in a patient with BRAF V600E+ papillary thyroid carcinoma
por: Bhethanabotla, Rohith M, et al.
Publicado: (2023)

T3 therapy for hypothyroidism: choosing wisely still requires careful bench to bedside translation
por: Dora, Jose Miguel, et al.
Publicado: (2021)

Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma
por: Li, Qian, et al.
Publicado: (2017)

Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer
por: Ivković, Irena, et al.
Publicado: (2022)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Correlation between Ultrasonographic Appearance of Papillary Thyroid Microcarcinoma and BRAF V600E Mutation
por: Liang, Songnian, et al.
Publicado: (2022)

Comparative BRAF V600E immunohistochemical expression in differentiated thyroid tumors with papillary features
por: Wahid, Maha Hatem Abdul, et al.
Publicado: (2022)

Patterns of radioiodine use for differentiated thyroid carcinoma in Brazil: insights and a call for action from a 20-year database
por: Schwengber, Wallace Klein, et al.
Publicado: (2020)

The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAF(V600E) Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old
por: Giles Şenyürek, Yasemin, et al.
Publicado: (2022)

A thyroid gland with over 30 foci of papillary thyroid carcinoma with activating BRAF V600E mutation
por: Pancer, Jill, et al.
Publicado: (2019)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Association between BRAF(V600E) mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma
por: Lu, Hai-Zhen, et al.
Publicado: (2017)

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
por: Ge, Junshang, et al.
Publicado: (2020)

Clinical Significance of PEAK1 Expression and BRAF V600E Mutation in Papillary Thyroid Cancer
por: Li, P., et al.
Publicado: (2022)

The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population
por: Ye, Ziheng, et al.
Publicado: (2022)

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation
por: Han, Ying, et al.
Publicado: (2022)

OR09-4 Novel Murine Models of BrafV600E driven Papillary Thyroid Cancer
por: Casado Medrano, Victoria, et al.
Publicado: (2022)

BRAF(V600E) Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
por: Park, Joonseon, et al.
Publicado: (2023)

Prevalence of BRAF(V600E) Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF(V600E) Prevalent Area
por: Kim, Hyereen, et al.
Publicado: (2018)

BRAF in Papillary Thyroid Carcinoma
por: Lanzilotta, Salvatore Giovanni, et al.
Publicado: (2007)

Clinical Outcome, Role of BRAF(V600E), and Molecular Pathways in Papillary Thyroid Microcarcinoma: Is It an Indolent Cancer or an Early Stage of Papillary Thyroid Cancer?
por: Nucera, Carmelo, et al.
Publicado: (2012)

Treatment strategies for low-risk papillary thyroid carcinoma: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)
por: Ward, Laura Sterian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9ktut8haig40tk4a9s04a509cf